Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.02 USD | -2.49% |
|
-4.71% | -66.01% |
12:05pm | Wolfe Research Downgrades 10x Genomics to Peer Perform From Outperform | MT |
25/06 | Guggenheim Downgrades 10x Genomics to Neutral From Buy | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-66.01% | 233.43Cr | |
-9.89% | 1.16TCr | |
-12.79% | 737.49Cr | |
+28.65% | 544.24Cr | |
+0.41% | 530.74Cr | |
-17.87% | 374.07Cr | |
+7.41% | 257.81Cr | |
+28.84% | 222.83Cr | |
-11.30% | 220.67Cr | |
-14.32% | 166.58Cr |
- Stock Market
- Equities
- TXG Stock
- News 10x Genomics, Inc.
- Transcript : 10x Genomics, Inc., Q1 2024 Earnings Call, Apr 30, 2024